The 2026 semi-annual reports and performance forecasts of listed innovative pharmaceutical companies were centrally disclosed, and the industry officially ushered in the triple performance inflection point of commercial single product release, overseas BD fulfillment, and high prosperity of the entire upstream CXO chain. In addition to popular products such as zebutinib and Maxidopeptide, which have achieved large-scale profits, as well as Shijiao Group, Hengrui Pharmaceuticals, and Cinda Biotech have successively launched 10 billion offshore BD orders. CXO's leading profits hit record highs at the same time as orders. According to industry experts, the performance of innovative pharmaceuticals in the first half of the year was not a short-term pulse, but rather a turning point from single product launch and single pipeline licensing to systematization of the entire industry chain; however, there is still a significant gap between domestic companies compared to multinational pharmaceutical companies such as Johnson & Johnson and Eli Lilly, and the industry still requires long-term efforts to catch up.

The 2026 semi-annual reports and performance forecasts of listed innovative pharmaceutical companies were centrally disclosed, and the industry officially ushered in the triple performance inflection point of commercial single product release, overseas BD fulfillment, and high prosperity of the entire upstream CXO chain. In addition to popular products such as zebutinib and Maxidopeptide, which have achieved large-scale profits, as well as Shijiao Group, Hengrui Pharmaceuticals, and Cinda Biotech have successively launched 10 billion offshore BD orders. CXO's leading profits hit record highs at the same time as orders. According to industry experts, the performance of innovative pharmaceuticals in the first half of the year was not a short-term pulse, but rather a turning point from single product launch and single pipeline licensing to systematization of the entire industry chain; however, there is still a significant gap between domestic companies compared to multinational pharmaceutical companies such as Johnson & Johnson and Eli Lilly, and the industry still requires long-term efforts to catch up.